Democratic Rep. Alexandria Ocasio-Cortez on Thursday confronted the CEO of the drug company Gilead over the high cost of an HIV-prevention drug.
Ocasio-Cortez asked why the drug Truvada costs nearly $2,000 per month in the US compared to $8 in Australia.
Gilead CEO Daniel O’Day said that the current monthly list price ($1,780) is a product of the drug’s “patent protection” in the US, while a generic version of the drug is sold in other countries.
The drug was developed by the US government with taxpayer funds, which Ocasio-Cortez zeroed in on as she rebuked the high cost of Truvada.
Visit BusinessInsider.com for more stories.
Democratic Rep. Alexandria Ocasio-Cortez of New York on Thursday confronted a drug company CEO about the high cost of an HIV-prevention drug.
Speaking to Gilead CEO Daniel O’Day, Ocasio-Cortez asked why the drug Truvada for PrEP (pre-exposure prophylaxis), which can help reduce the risk of contracting HIV via sex, cost nearly $2,000 per month in the US, versus $8 in Australia.
O’Day said that the current monthly list price ($1,780) is a product of the drug’s “patent protection” in the US, while a generic version of the drug is sold in other countries.
The Gilead CEO did not offer specifics on the price in Australia, but reports suggest the generic drug costs somewhere in the range of $5 to $30 in the country, depending on the person’s circumstances. He also said that the drug will be generically available in the US as of September 2020.
Ocasio-Cortez went on to slam the cost of the drug in the US, stating the “people are dying” because it’s not affordable enough.
.@AOC to Gilead CEO: The list price [for Truvada for PrEP] is almost $2,000 in the US. Why is it $8 in Australia? pic.twitter.com/kPnMQSZE0G
— Public …read more
Source:: Business Insider